Nivolumab in Treating Patients With Advanced Metastatic Non-small Cell Lung Cancer

Part of paid clinical trials in Atlanta, Georgia.

Sponsor
Emory University
Study ID
NCT03121417
Phase
PHASE2
Status
Withdrawn

Conditions

  • Recurrent Non-Small Cell Lung Carcinoma
  • Stage IV Non-Small Cell Lung Cancer

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

This phase II trial is studying blood and tumor tissue from patients with advanced non-small cell lung cancer who are treated with nivolumab to better understand how nivolumab works. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread by turning on the immune system (T cells). We want to study the effects of nivolumab on the immune system (T cells) by collecting blood samples and samples from patients' tumors.

Key Dates

Start date
Jul 21, 2017
Status verified
May 2019
Primary completion
Mar 9, 2019
Completion
Mar 9, 2019

Study Design

Enrollment
0 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Treatment (nivolumab)
    Patients receive nivolumab IV over 30 minutes on day 1. Courses repeat every 2 weeks in the absence of disease progression or unexpected toxicity

Primary Outcome Measure

Objective response rate (ORR) [ Time Frame: Up to 3 years after study start ]

Locations (2)

FacilityCityStateZIPSite coordinators
Emory University Hospital MidtownAtlantaGeorgia30308-
Emory University/Winship Cancer InstituteAtlantaGeorgia30322-

Find similar trials in Atlanta, GA

By research site
Emory University Hospital Midtown· Atlanta, GAEmory University/Winship Cancer Institute· Atlanta, GA

Related Studies